Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Chu

Showing results (111-120 of 130) with videos related to

Pageof 13
Sort By:
European Urology Oncology|February 4, 2025
Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective TrialsCristian Udovicich, Patrick Cheung, William Chu, et al.
International Journal of Radiation Oncology, Biology, Physics|January 29, 2020
Evaluating the Tolerability of a Simultaneous Focal Boost to the Gross Tumor in Prostate SABR: A Toxicity and Quality-of-Life Comparison of Two Prospective TrialsYasir Alayed, Melanie Davidson, Stanley Liu, et al.
European Urology Oncology|April 27, 2025
Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body RadiotherapyWee Loon Ong, Harvey Quon, Aldrich Ong, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 3, 2019
Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trialsYasir Alayed, Harvey Quon, Patrick Cheung, et al.
European Urology|August 17, 2021
Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter StudyPatrick Cheung, Samir Patel, Scott A North, et al.
JAMA Network Open|February 25, 2026
SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate CancerCristian Udovicich, Patrick Cheung, William Chu, et al.
Current Biology : CB|February 14, 2017
The Macronuclear Genome of Stentor coeruleus Reveals Tiny Introns in a Giant CellMark M Slabodnick, J Graham Ruby, Sarah B Reiff, et al.
The Lancet. Oncology|November 18, 2022
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)Shankar Siva, Muhammad Ali, Rohann J M Correa, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 7, 2019
Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapyYasir Alayed, Melanie Davidson, Harvey Quon, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
Pageof 13

Showing results (111-120 of 130) with videos related to

Sort By:
Pageof 13
European Urology Oncology|February 4, 2025
Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective TrialsCristian Udovicich, Patrick Cheung, William Chu, et al.
International Journal of Radiation Oncology, Biology, Physics|January 29, 2020
Evaluating the Tolerability of a Simultaneous Focal Boost to the Gross Tumor in Prostate SABR: A Toxicity and Quality-of-Life Comparison of Two Prospective TrialsYasir Alayed, Melanie Davidson, Stanley Liu, et al.
European Urology Oncology|April 27, 2025
Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body RadiotherapyWee Loon Ong, Harvey Quon, Aldrich Ong, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 3, 2019
Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trialsYasir Alayed, Harvey Quon, Patrick Cheung, et al.
European Urology|August 17, 2021
Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter StudyPatrick Cheung, Samir Patel, Scott A North, et al.
JAMA Network Open|February 25, 2026
SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate CancerCristian Udovicich, Patrick Cheung, William Chu, et al.
Current Biology : CB|February 14, 2017
The Macronuclear Genome of Stentor coeruleus Reveals Tiny Introns in a Giant CellMark M Slabodnick, J Graham Ruby, Sarah B Reiff, et al.
The Lancet. Oncology|November 18, 2022
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)Shankar Siva, Muhammad Ali, Rohann J M Correa, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 7, 2019
Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapyYasir Alayed, Melanie Davidson, Harvey Quon, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
Pageof 13